Volume 4.44 | Nov 8

Mammary Cell News 4.44 November 8, 2012
Mammary Cell News
     In this issue: Publications | Reviews Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Microfluidics Separation Reveals the Stem-Cell-Like Deformability of Tumor-Initiating Cells
Scientists demonstrated the separation of (i) a mixture of two breast cancer cell types with distinct deformabilities and metastatic potentials, and (ii) a heterogeneous breast cancer cell line, into enriched flexible and stiff subpopulations. [Proc Natl Acad Sci USA] Abstract | Press Release

Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video
PUBLICATIONS (Ranked by impact factor of the journal)


Nitric Oxide Dependent Downregulation of BRCA1 Expression Promotes Genetic Instability
Researchers found that nitric oxide/reactive nitrogen species stimulates genetic instability by inhibiting BRCA1-expression and shifting DNA repair from high-fidelity to error-prone mechanisms. [Cancer Res] Abstract

Control of Breast Cancer Growth and Initiation by the Stem Cell-Associated Transcription Factor TCF
TCF3 is a member of the TCF/LEF transcription factor family that is central in regulating epidermal and embryonic stem cell identity. Researchers found that TCF3 is highly expressed in poorly differentiated human breast cancers, preferentially of the basal-like subtype. [Cancer Res] Abstract

A New Mouse Model for the Study of Human Breast Cancer Metastasis
Researchers describe a novel in vivo model using human breast cancer xenografts in NOD scid gamma mice; in this model human breast cancer cells reliably metastasize to distant organs from primary tumors grown within the mammary fat pad. [PLoS One] Full Article

Phenotype-Dependent Effects of EpCAM Expression on Growth and Invasion of Human Breast Cancer Cell Lines
The epithelial cell adhesion molecule (EpCAM) has been shown to be overexpressed in breast cancer and stem cells and has emerged as an attractive target for immunotherapy of breast cancer patients. Investigators analyzed the effects of EpCAM on breast cancer cell lines with epithelial or mesenchymal phenotype. [BMC Cancer] Abstract | Full Article

Cancer Stem Cell Markers CD44, CD24 and ALDH1 in Breast Cancer Special Histological Types
Scientists aimed to determine the distribution of the breast CD44, CD24 and ALDH1 cancer stem cell markers among a series of invasive breast carcinomas of special histological types, in comparison with a series of invasive ductal carcinomas of no special type. [J Clin Pathol] Abstract 

International Multicenter Tool to Predict the Risk of Nonsentinel Node Metastases in Breast Cancer
Investigators aimed to develop a novel multi-institutional predictive tool to calculate patient-specific risk of residual axillary disease after tumor-positive sentinel node biopsy. [J Natl Cancer Inst] Abstract

Triple Negative Breast Cancer and Phosphatase and Tensin Homolog Loss Are Predictors of BRCA1 Germline Mutations in Women with Early Onset and Familial Breast Cancer, But Not in Women with Isolated Late-Onset Breast Cancer
Germline mutations in BRCA1 and BRCA2 were analyzed by Sanger sequencing and multiple ligation dependent probe amplification analysis in 431 women from the Malaysian Breast Cancer Genetic Study, including 110 women with triple negative breast cancer. [Breast Cancer Res] Abstract | Full Article

Doxorubicin Influences the Expression of Glucosylceramide Synthase in Invasive Ductal Breast Cancer
Investigators collected 84 excision biopsies from patients with invasive ductal breast cancer of whom 33 patients had undergone preoperative chemotherapy. Immunohistochemistry was used to analyze the expression of glucosylceramide synthase (GCS) protein and significantly showed that the expression of GCS was higher in the samples from patients treated with preoperative chemotherapy. [PLoS One] Full Article

Clinical Usefulness of Human Epidermal Growth Factor Receptor-2 Extracellular Domain as a Biomarker for Monitoring Cancer Status and Predicting the Therapeutic Efficacy in Breast Cancer
Researchers assessed the clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for detecting cancer and monitoring disease status and for predicting the efficacy of anticancer treatment in breast cancer. [Cancer Biol Ther] Abstract

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells


Cytokines, Obesity, and Cancer: New Insights on Mechanisms Linking Obesity to Cancer Risk and Progression
This review summarizes the how cytokine production in obese adipose tissue creates a chronic inflammatory microenvironment that favors tumor cell motility, invasion, and epithelial-mesenchymal transition to enhance the metastatic potential of tumor cells. [Annu Rev Med] Abstract

Breast Cancer Stem Cells: A Novel Therapeutic Target
This review discusses the emergence and expediency of breast cancer stem cells in treating relapse and advanced cases of breast cancer. [Clin Breast Cancer] Abstract


Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Nektar Therapeutics announced that the U.S. Food and Drug Administration has designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine. [Nektar Therapeutics] Press Release

Early Economic Evaluation from GE Healthcare Highlights the Potential Benefits of Biomarker-Directed Care in Breast Cancer and Renal Cell Carcinoma
GE Healthcare announced results of three health economic models to estimate the potential cost offsets to the healthcare system of biomarker testing in patients with early breast cancer, metastatic breast cancer and renal cell carcinoma to guide therapy selection. These studies were presented at the International Society for Pharmacoeconomics and Outcomes Research 15th European Congress in Berlin, Germany. [GE Healthcare] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW TM’s 2nd World Cancer Online Conference
January 8-11, 2013

our events page to see a complete list of events in the mammary cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Associate Attending Breast Pathologist (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Higher Scientific Officer – Histopathology/Breast Pathology (Institute of Cancer Research)

Laboratory Heads – Developmental Biology and Stem Cell Biology (RIKEN Center for Developmental Biology)

Postdoctoral Fellow – Cancer Genomics (Mayo Clinic Florida)

Research Fellow – Division of Solid Tumor Oncology (Dana-Farber Cancer Institute)

Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us